Clinical trial · Interventional
Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments
NCT04825925CI-TRIAL-00051199unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, prospective, single-arm clinical study to determine the efficacy and safety of Drug-eluting beads bronchial arterial chemoembolization(DEB-BACE) in stage II-III NSCLC patients who failed, refused or ineligible to receive standard treatments
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DEB-BACE
- interventionNames
- Device: DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- Time from the first DEB-BACE treatment to either radiological progression after the second DEB-BACE treatment or death, up to 36 months
- description
- Time from the first DEB-BACE treatment to either radiological progression after the second DEB-BACE treatment or death
Secondary outcomes (8)
- measure
- Objective response rate (ORR)
- timeFrame
- 1, 3, 6 months after the first DEB-BACE treatment, up to death or 36months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients ≥ 18 years old, of any sex; 2. Patients who have histopathological proof of NSCLC according to the standard of diagnosis and treatment of primary lung cancer(V2018); 3. Confirmed TNM stage is II-III of NSCLC; 4. Patients who were failed, refused or assessed ineligible by MDT to receive conventional Second-Line treatments (surgery, chemoradiotherapy, targeted and immunotherapy); 5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2; 6. Life expectancy of \> 3 months; 7. Patients volunteered to participate in this study and signed informed consent, with good compliance; Exclusion Criteria: 1. Patients received interventional therapy (I seeds implantation, Ablation, BACE) before; 2. A history combined with other malignant tumors and not cured; 3. WBC\<3×109/L、LYM\<1.5×109/L、NLR≥3、PLT\<50×109/L、HGB\<90 g/L; 4. Insufficient of liver and renal function (Cr\>176.8 µmol/L; AST and/or ALT\>2 folds of normal value); 5. Combined with uncorrectable coagulation dysfunction or active massive hemoptysis; 6. Combined with active affection and need antibiotic treatment; 7. Uncontrollable hypertension, diabetes, cardiovascular disease with obvious symptoms; 8. Known to be hypersensitive to contrast agent; 9. Pregnant or breastfeeding women;
References
Publications (0)
Data not yet available
No reference posted for this study.